Cargando…
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
INTRODUCTION: Since the launch of drotrecogin alfa activated (DrotAA), institutions and individual countries have published data on its use in clinical practice, based on audit or registry data. These studies were limited in size and geographic locale and included patients with greater disease sever...
Autores principales: | Martin, Greg, Brunkhorst, Frank M, Janes, Jonathan M, Reinhart, Konrad, Sundin, David P, Garnett, Kassandra, Beale, Richard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717475/ https://www.ncbi.nlm.nih.gov/pubmed/19566927 http://dx.doi.org/10.1186/cc7936 |
Ejemplares similares
-
Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007) -
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2008) -
Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007) -
Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008) -
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2010)